Bullseye Biodevices Selected to Present at the Prestigious New York Venture Summit

HOBOKEN, NJ – We are excited to announce that Bullseye Biodevices has been selected to present at the 2026 New York Venture Summit, taking place November 18–19, 2026, at the Javits Center in New York City.

Hosted by youngStartup Ventures, the New York Venture Summit brings together innovative companies, venture capital firms, corporate investors, angel networks, and industry leaders from across the country.

This year, the Summit will spotlight 190 Top Innovators across sectors that are shaping the future of healthcare, technology, energy, AI, and other emerging industries. We are honored to be among the companies selected to present.

At the Summit, we will showcase Bullseye’s multimodal biosensing platform, which is designed to transform hidden biological signals into actionable information for smarter healthcare decision-making.

Our initial focus is precision tumor detection during minimally invasive and robotic surgery. By combining complementary biosensing modalities, our technology is being developed to help surgeons localize tumors, characterize tissue, and assess surgical margins in real time.

“Being selected for the New York Venture Summit is an incredible honor,” said Donnie Mir, PhD, Co-Founder and Chief Executive Officer of Bullseye Biodevices. "We are excited to share our vision, connect with investors and industry leaders, and continue advancing technologies that can bring real-time tissue intelligence into healthcare decision-making.”

The New York Venture Summit will also feature venture panels, roundtable discussions, and networking opportunities designed to connect entrepreneurs with investors and strategic partners.

We look forward to presenting Bullseye at the New York Venture Summit on November 19 and sharing the next stage of our journey.

About Bullseye Biodevices, Inc.

Founded in 2024, Bullseye Biodevices, Inc. is developing multimodal biosensing technologies for real-time tissue assessment. To date, Bullseye has received NSF STTR Phase I funding and secured a $1.3 million strategic investment, and has continued building a global intellectual property portfolio around its biosensing technologies.

About Venture Summit

Hosted by youngStartup Ventures, the New York Venture Summit convenes the brightest entrepreneurs, investors, and thought leaders driving innovation forward. Over two dynamic days, attendees explore the trends, technologies, and partnerships defining the future economy.

November 2026